Joaqim Trias, PhD

President, JPTS Consulting, USA

Dr. Trias has spent over 25 years in drug discovery and development, in both academia and industry. His research interests have focused on mechanism of action of new drugs and mechanism of resistance to antibiotics. Dr. Trias obtained his Ph.D. at the University of Barcelona and completed his post-doctoral training at the University of California at Berkeley. He has held different academic positions, he was previously a Research Fellow at the School of Medicine Pitié–Salpêtrière of the University of Paris VI, and later on was also appointed Professor of Microbiology at the Faculty of Pharmacy of the University of Barcelona.

In 1990 he joined Microcide Pharmaceuticals where he led various discovery programs in infectious diseases. He left Microcide to join Versicor (later named Vicuron) where he was Vice President of Drug Discovery Research at Vicuron and directed the internal discovery projects of novel antibiotics and antifungal‚ from concept to clinical candidate and participated in the clinical development programs. He moved to Anthera where he led the preclinical development programs of novel therapeutics for the treatment of autoimmune, cardiovascular, and sickle cell diseases. He is the co-founder of Peninsula, Anthera, and Tetraphase. He currently serves as a consultant and advisor, through JTPS Consulting, for Venture Capital firms and Pharmaceutical Companies.